Lidoflazine is a synthetic drug with calcium-channel blocking effects. In a study of 6 patients with severe classic angina pectoris, single-blind administra tion of lidoflazine was associated with improved myocardial perfusion during exercise as determined by thallium-201 stress scintigraphy. These studies demonstrate that lidoflazine therapy is associated with relief of angina, an increased physical work capacity, and improved regional myocardial perfusion during exercise.
Get full access to this article
View all access options for this article.
References
1.
Vanhoutte PM, Van Neuten JM: The pharmacology of lidoflazine. In: Myocardial Protection and Exercise Tolerance: The Role of Lidoflazine, a New Anti-anginal Agent . Royal Society of Medicine International Congress and Symposium Series No. 29. London, Royal Society of Medicine and Academic Press, 1980, pp. 61-77.
2.
Naylor WG: The protective effect of lidoflazine on ischemic and reperfused heart muscle . In: Myocardial Protection and Exercise Tolerance: The Role of Lidoflazine, a New Anti-anginal Agent. Royal Society of Medicine International Congress and Symposium Series No. 29. London, Royal Society of Medicine and Academic Press , 1980, pp. 79.87.
3.
Bernstein V. , Peretz DI: Liodoflazine. A new drug in the treatment of angina pectoris. Curr Ther Res14:483, 1972.
4.
Piessens J., DeGeest H: Long term evaluation of lidoflazine in angina pectoris based on exercise tolerance. Cardiology57:135, 1972.
5.
Jageneau A., Brugmans J.: The effect of lidoflazine on the exercise capacity of normal volunteers; double-blind cycloergometric evaluations. Arzneim Forsch22:457, 1972.
6.
Nordstrom LA , Gobel FL: The effects of lidoflazine on exercise tolerance in patients with angina pectoris . Chest74:50, 1978.
7.
Ritchie JL, Trobaugh GB, Hamilton GW, et al: Myocardial imaging with thallium-201 at rest and during exercise: comparison with coronary arteriography and resting and stress electrocardiography . Circulation56:66, 1977.
8.
Nixon JV, Narahara KA, Smitherman TC: Estimation of myocardial involvement in patients with acute myocardial infarction by two-dimensional echocardiography. Circulation62:1248, 1980.
9.
Alfonso S., O'Brien GS, Crumpton CW: Enhancement of coronary vasodilator action of ATP and adenosine after lidoflazine (R 7904). J Lab Clin Med68:852, 1966.
10.
Gobel FL, Nordstrom LA, Nelson RR, Ketola E.: The effect of lidoflazine on myocardial performance and blood flow in patients with angina pectoris. In: Second Lidoflazine Symposium . Ed by Hochrein H. Hamburg, Perimed Verlag, 1975, pp. 139-149.
11.
Livesley B. , Catley PF, Campbell RC, Oram S.: Double-blind evaluation of verapamil, propranolol and isosorbide dinitrate against a placebo in the treatment of angina pectoris . Br Med J1:375, 1973.
12.
Malacoff RF , Lorell BH, Mudge BH Jr, et al: Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease . Circulation65(Suppl I):32-37, 1982.
13.
Hossack KF, Bruce RA, Ritterman JB, et al:Divergent effects of diltiazem in patients with exertional angina. Am J Cardiol49:538-546, 1982.
14.
Epstein SE, Talbot TL: Dynamic coronary tone in precipitation, exacerbation, and relief of angina pectoris. Am J Cardiol48:797, 1981.
